Innate Pharma S.A. announced that a set of pharmacological data, from Research to clinical Phase II, of its drug candidate IPH 1101 was presented at the "American Society of Clinical Oncology" annual meeting.
| PR in english | 141.72 KB |
| CP en français | 141.53 KB |